UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 557

Sortiert nach

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

Nature reviews. Rheumatology, 2020-10, Vol.16 (10), p.581-589

2020

Volltextzugriff (PDF)

What Did Not Work: The Drug or the Trial?

Arthritis & rheumatology (Hoboken, N.J.), 2021-10, Vol.73 (10), p.1773-1775

Merrill, Joan T.

2021

Volltextzugriff (PDF)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2017-02, Vol.69 (2), p.376-386

2017

Volltextzugriff (PDF)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study

Arthritis & rheumatology (Hoboken, N.J.), 2018-02, Vol.70 (2), p.266-276

2018

Volltextzugriff (PDF)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Annals of the rheumatic diseases, 2016-11, Vol.75 (11), p.1909-1916

2016

Volltextzugriff (PDF)

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Annals of the rheumatic diseases, 2018-06, Vol.77 (6), p.883

2018

Volltextzugriff (PDF)

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

Arthritis & rheumatology (Hoboken, N.J.), 2014-02, Vol.66 (2), p.379-389

2014

Volltextzugriff (PDF)

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

Arthritis care & research (2010), 2012-06, Vol.64 (6), p.797-808

2012

Volltextzugriff (PDF)

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Annals of the rheumatic diseases, 2016-01, Vol.75 (1), p.196-202

2016

Volltextzugriff (PDF)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis & rheumatology (Hoboken, N.J.), 2023-02, Vol.75 (2), p.242-252

2023

Volltextzugriff (PDF)

Tissue factor upregulation is associated with SARS‐CoV‐2 in the lungs of COVID‐19 patients

Journal of thrombosis and haemostasis, 2021-09, Vol.19 (9), p.2268-2274

2021

Volltextzugriff (PDF)

Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study

Annals of internal medicine, 2015-08, Vol.163 (3), p.153

2015

Volltextzugriff (PDF)

Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort

Arthritis & rheumatology (Hoboken, N.J.), 2021-12, Vol.73 (12), p.2293-2302

2021

Volltextzugriff (PDF)

Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity

Arthritis research & therapy, 2013-01, Vol.15 (6), p.R212-R212

2013

Volltextzugriff (PDF)

SARS-CoV-2 vaccines in patients with SLE

Lupus science & medicine, 2021-03, Vol.8 (1), p.e000479

2021

Volltextzugriff (PDF)

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

The New England journal of medicine, 2022-03, Vol.386 (11), p.1034-1045

2022

Volltextzugriff (PDF)

Co-stimulatory molecules as targets for treatment of lupus

Clinical immunology (Orlando, Fla.), 2013-09, Vol.148 (3), p.369-375

Merrill, Joan T

2013

Volltextzugriff (PDF)

Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study

American journal of obstetrics and gynecology, 2016-01, Vol.214 (1), p.108.e1-108.e14

2016

Volltextzugriff (PDF)

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

Lupus, 2021-07, Vol.30 (8), p.1254-1263

2021

Volltextzugriff (PDF)

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

Rheumatology (Oxford, England), 2020-10, Vol.59 (10), p.2930-2938

2020

Volltextzugriff (PDF)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1125-1134

2019

Volltextzugriff (PDF)

Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies

Annals of the rheumatic diseases, 2018-04, Vol.77 (4), p.549

2018

Volltextzugriff (PDF)

Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non‐Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares

Arthritis & rheumatology (Hoboken, N.J.), 2016-09, Vol.68 (9), p.2200-2209

2016

Volltextzugriff (PDF)

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Annals of the rheumatic diseases, 2012-11, Vol.71 (11), p.1833-1838

2012

Volltextzugriff (PDF)

Optimization of current and future therapy for autoimmune diseases

Nature medicine, 2012-01, Vol.18 (1), p.59-65

2012

Volltextzugriff (PDF)

1 – 25 von 557

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(389)
Mit Volltextzugriff
(449)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(556)
Japanisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(268)
Life Sciences & Biomedicine
(259)
Humans
(246)
Rheumatology
(201)
Female
(154)
Lupus
(142)
Male
(127)
Systemic Lupus Erythematosus
(125)
Adult
(120)
Middle Aged
(81)
Biological And Medical Sciences
(80)
Medical Sciences
(77)
Lupus Erythematosus, Systemic - Drug Therapy
(69)
Medicin Och Hälsovetenskap
(66)
Lupus Erythematosus, Systemic - Immunology
(64)
Autoimmune Diseases
(59)
Lupus Erythematosus, Systemic - Genetics
(54)
Risk Factors
(53)
Severity Of Illness Index
(51)
Diseases Of The Osteoarticular System
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

What Did Not Work: The Drug or the Trial?

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Tissue factor upregulation is associated with SARS‐CoV‐2 in the lungs of COVID‐19 patients

Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study

Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort

Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity

SARS-CoV-2 vaccines in patients with SLE

Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

Co-stimulatory molecules as targets for treatment of lupus

Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus

Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies

Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non‐Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Optimization of current and future therapy for autoimmune diseases

Suchergebnisse filtern